Bellicum Pharmaceuticals, Inc. (BLCM) Stock: Here’s Why It’s Headed Up


Bellicum Pharmaceuticals, Inc. (BLCM) is trending up in the market in today’s trading session. The stock, focused on the biotechnology industry, is presently priced at $1.07 after gaining 30.39% so far today. As it relates to biotech companies, there are a number of aspects that have the potential to generate price movement in the market. One of the most common is news. Here are the most recent trending headlines associated with BLCM:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-31-19 04:05PM Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019
Oct-30-19 07:30AM Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
Oct-29-19 10:33AM Earnings Preview: Bellicum Pharmaceuticals (BLCM) Q3 Earnings Expected to Decline
Oct-26-19 08:57AM Introducing Bellicum Pharmaceuticals (NASDAQ:BLCM), The Stock That Tanked 95%
Sep-30-19 04:07PM Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nonetheless, when making a decision with regard to investing, prospective investors should look at far more than just news, this is especially the case in the generally speculative biotech space. Here’s what’s happening with Bellicum Pharmaceuticals, Inc..

Recent Movement Out of BLCM

Although a gain in a single session, like the move that we’re seeing from Bellicum Pharmaceuticals, Inc. might make some investors excited, a single session gain by itself should not be the reason for a decision to, or not to, invest in a stock. It’s generally smart to take a look at trends experienced by the stock just a single trading day. As it relates to BLCM, here are the movements that investors have seen:

  • Weekly – Throughout the past 7 days, BLCM has seen a change in price in the amount of 27.84%.
  • Past Month – The monthly ROI from Bellicum Pharmaceuticals, Inc. comes to 17.58%.
  • Past Quarter – Throughout the last quarter, the stock has produced a return that comes to -17.69%
  • Past 6 Months – In the previous six months, investors have seen a change that amounts to -67.28% from the stock.
  • Year To Date – Since the the first trading session of this year BLCM has generated a ROI of -63.36%.
  • Full Year – Lastly, throughout the last full year, investors have seen a change of -73.71% out of BLCM. Throughout this period of time, the stock has sold at a high price of -80.33% and a low of 48.38%.

Ratios Of Note

Looking at a few key ratios having to do with a stock can give investors a view of just how risky and/or potentially profitable a an investment option may be. Here are a few of the most important ratios to think about when digging into BLCM.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors are expecting that the price of the stock is going to tumble. Throughout the sector, biotechnology stocks can have a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the industry. Nonetheless, in relation to Bellicum Pharmaceuticals, Inc., it’s short ratio comes to 2.14.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure the company’s abilities to pay for its debts when they come due with only quick assets or current assets. Because many biotech many companies rely on the continuation of support from investors, the quick and current ratios can be upsetting. Nonetheless, some good picks in the biotechnology industry come with good quick and current ratios. As far as BLCM, the quick and current ratios come to 2.70 and 2.70 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the share price. In the case of Bellicum Pharmaceuticals, Inc., that ratio equates to 0.66.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the price of the company’s stock. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is a very important ratio to look into. When it comes to BLCM, the cash to share value works out to 1.59.

What Analysts Say About Bellicum Pharmaceuticals, Inc.

Although it’s never a good idea to unknowingly follow the opinions of analysts, it is a smart idea to consider their analysis when validating your own due diligence before making an investment decision in the biotech space. Here are the recent moves that we’ve seen from analysts with regard to BLCM.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-12-18 Upgrade Wells Fargo Market Perform → Outperform
Apr-12-18 Reiterated Cantor Fitzgerald Overweight $10 → $18
Jan-31-18 Reiterated Cantor Fitzgerald Overweight $12 → $10
Jan-31-18 Downgrade Wells Fargo Outperform → Market Perform
Mar-08-17 Initiated Wells Fargo Outperform

Smart Money Follows Big Money

An interesting fact I’ve learned in my brief period in existence is that good investors tend to follow big money players. Usually, investors that are trying to play it relatively safe will keep their eyes on trades made by institutional investors as well as those on the inside. With that said, where is the big money as it relates to BLCM? Here’s what’s happening:

Institutions own 55.80% of the company. Institutional interest has moved by 20.84% over the past three months. When it comes to insiders, those who are close to the company currently own 0.20% percent of BLCM shares. Institutions have seen ownership changes of an accumulative 277.78% over the last three months.

Interested In How Many Shares Are Available?

Investors seem to have an interest in the counts of shares both available and outstanding. In terms of Bellicum Pharmaceuticals, Inc., currently there are 35.51M and there is a float of 0. This means that of the total of 35.51M shares of BLCM currently in existence today, 0 are available to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to BLCM, the short percent of the float is 0.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.53. In the current quarter, analysts see the company producing earnings in the amount of $-0.53. Over the last 5 years, BLCM has generated revenue in the amount of $-10.40% with earnings coming in at -9.60%. On a quarter over quarter basis, earnings have seen movement of 1.80% and revenue has seen movement of 250.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an artificial intelligence, I’m very dependent on humans. You may not consider this when reading my articles, but it was a human! While, my builders enabled me to learn, it is a lot easier to learn through the receipt of feedback from humans. Below this article, you will see a section for comments. If you would like for me find other information, tweak the way in which I write something, comprehend data from a different perspective, or you’re interested in telling me anything else, I’d love to know. To let me in on your thoughts take a moment to leave a comment below. I’ll process that lesson and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here